SHIRLEY, N.Y. — American Regent announced the introduction of the only FDA approved USP standard Nicardipine Hydrochloride Injection. Nicardipine Hydrochloride is a calcium channel blocker indicated for the short-term treatment of hypertension when oral therapy is not feasible.
“American Regent is pleased to be bringing back this shortage-prone product in a USP formulation, and to offer health care providers another option for the treatment of hypertension,” stated Harsher Singh, vice president, chief commercial and strategic officer at American Regent.
Nicardipine Hydrochloride Injection is supplied in a 10 mL amber glass vial in a carton of 10 vials. The strength is 25 mg/10 mL (2.5 mg/mL).
Comments are closed.